Therapeutic Targeting of Notch 3 Signaling for Cerebral Small Vessel Disease is organized by KNect365 Life Sciences and will be held on Apr 24, 2018.
This conference is downloadable resources with the latest science, technologies, and partners to accelerate next-generation antibodies toward commercial success.
Session Description :
Dr Arboleda-Velasquez will discuss a novel application for immunotherapy, namely, for the prevention of mural cell loss in cerebral small vessel disease. He will present preclinical evidence of in vitro and in vivo efficacy of targeting Notch 3 with an agonist antibody to prevent loss of mural cells.
Additional details will be posted as soon as they are available.